Chairman of Baofeng Biotechnology said: "We have been preparing for three years to enter the NASDAQ main board market in the United States." This year, Baofeng biotechnology has further optimized and improved the company's industrial layout, expanded the sales channels of nerve acid products, and the main business has increased significantly. "

The company hired a team of American professional lawyers, listed securities companies and American Securities Association registered audit companies, as well as investor relations team, including the structural design and rectification of listed companies, equity changes, and a series of mergers and acquisitions of companies at home and abroad. as well as the spin-off and restructuring of non-high-tech business and other preparations for listing in the United States.

In May 2019, the company hired an American certified public accounting firm specializing in international business to conduct a pre-listing audit of our company's three-year financial statements. The performance from 2016 to 2019 shows an upward trend year by year, and the performance in 2019 is the highest in the past three years, which will boost the stock price in the future. Auditors and US securities firms have suggested that in addition to the original financial reports for the three years from 2016 to 2018, the financial affairs of the first half of 2019 should be included in the listing audit to reflect the value of the stock, which is more conducive to being favored by securities firms and investment banks.

In order to meet the requirements of the US Securities Regulatory Commission and securities firms, the company's financial staff are cooperating with the auditors to complete all the financial summary work to ensure that the three-year financial data are accurately reported to the listing audit. At the same time, the company has also approached major investment funds and investment banks, and plans to conduct roadshows in various states across the United States, with an all-out effort to present to all shareholders with four consecutive years of increasing performance and high stock prices.